1-7 of 7
Zhijie Ding
Close
Save search
Sort by
Journal Articles

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Free
Kim Linton, John N. Allan, Andrew S Park, Anthony W Wang, Summer Tran, Alex Mutebi, Zhijie Ding, Quan Chen, Tycel J. Phillips
Journal: Blood
Blood (2024) 144 (Supplement 1): 1703.
https://doi.org/10.1182/blood-2024-200989
Published: 2024
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Free
Karen Cumings, Viktor Chirikov, Zhijie Ding, Felipe Marques Goncalves, Nicole Heaps, Savreet Bains Chawla, Anthony W Wang, Mohammad Atiya, Fernando Rivas Navarro, Elena Favaro, Daniela Hoehn, Alex Mutebi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7802.
https://doi.org/10.1182/blood-2024-200799
Published: 2024
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Free
Javier Munoz, Allison C. Rosenthal, Andrew Ip, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7760.
https://doi.org/10.1182/blood-2024-203876
Published: 2024
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Free
Andrew Ip, Javier Munoz, Allison C. Rosenthal, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7757.
https://doi.org/10.1182/blood-2024-203540
Published: 2024
Journal Articles

Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data

Free
John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P Qureshi, Susan M. O'Brien
Journal: Blood
Blood (2023) 142 (Supplement 1): 3278.
https://doi.org/10.1182/blood-2023-184318
Published: 2023
Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Free
Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers
Journal: Blood
Blood (2023) 142 (Supplement 1): 1915.
https://doi.org/10.1182/blood-2023-186284
Published: 2023
Journal Articles

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Free
Nilanjan Ghosh, Ruibin Wang, Zhijie Ding, Jinghua He, Alex Bokun, Heena Mavani, Zaina P Qureshi, Kerry A Rogers
Journal: Blood
Blood (2023) 142 (Supplement 1): 270.
https://doi.org/10.1182/blood-2023-187743
Published: 2023